



Balfour Capital Group STAAR Surgical Company

STAAR Surgical is a medical device company specializing in the design, development, manufacture, and marketing of implantable lenses for the eye, primarily for vision correction. Their flagship product, the EVO Implantable Collamer® Lens (EVO ICL™), offers an alternative to LASIK surgery for correcting myopia, hyperopia, and astigmatism. The company serves ophthalmic surgeons, vision centers, hospitals, and distributors worldwide.

1. Top 5 Competitors

STAAR Surgical's main competitors in the ophthalmic and vision correction industry include:

- Alcon Inc. (Switzerland)
- Bausch Health Companies Inc. (Canada)
- Hoya Corporation (Japan)
- Carl Zeiss Meditec AG (Germany)
- Johnson & Johnson Vision (USA)

2. Largest Institutional Shareholders

As of the latest filings, significant institutional shareholders of STAAR Surgical include:

- Broadwood Capital, Inc. – 27.46% ownership
- BlackRock Advisors LLC – 14.85%
- Vanguard Fiduciary Trust Co. – 10.98%
- Armistice Capital LLC – 6.08%

Overall, institutional investors hold approximately 48.21% of the company's stock.

3. Management Team

Key members of STAAR Surgical's management team include:

- Stephen C. Farrell – Chief Executive Officer (appointed February 2025)
- Warren Foust – President & Chief Operating Officer
- Deborah Andrews – Interim Chief Financial Officer
- Magda Michna, PhD – Chief Development Officer
- Nathaniel Sisitsky – Senior Vice President



Balfour Capital Group STAAR Surgical Company

4. Revenue

For the fiscal year 2024, STAAR Surgical reported net sales of \$313.9 million, a decrease from \$322.4 million in the prior year. The decline was primarily due to reduced sales in China.

In the first quarter of 2025, the company reported revenue of \$42.6 million, representing a 45% year-over-year decrease.

5. Institutions with Buy Recommendations:

Notable institutions that have issued buy recommendations for STAAR Surgical include:

- Needham & Company – Maintained a Buy rating as of September 2023.
- Stifel – Upgraded the stock to Buy in March 2024, citing undervaluation and potential for sales growth.

6. Analyst Sentiment Summary

As of May 2025, analyst sentiment for STAAR Surgical is as follows:

- Buy Ratings: 2
- Hold Ratings: 10
- Sell Ratings: 1

The consensus rating is "Hold," with an average 12-month price target of \$19.14.

7. Insider Buying and Selling (Last 24 Months)

Over the past 24 months, insider activity includes:

- Total Shares Purchased: 3,129,077
- Total Value of Purchases: \$75,000,843.92

Notable insider purchases:

- Aimee S. Weisner: \$164,132.50
- Arthur C. Butcher: \$49,956.85
- Broadwood Partners, L.P.: \$74,686,754.57
- Elizabeth Yeu Lin: \$100,000.00

There have been no reported insider sales during this period.